🇺🇸 Palbociclib 125mg in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 12

Most-reported reactions

1. Fatigue — 2 reports (16.67%)
2. Respiratory Failure — 2 reports (16.67%)
3. Abdominal Pain — 1 report (8.33%)
4. Asthenia — 1 report (8.33%)
5. Back Pain — 1 report (8.33%)
6. Cellulitis — 1 report (8.33%)
7. Diarrhoea — 1 report (8.33%)
8. Dyspnoea — 1 report (8.33%)
9. Hilar Lymphadenopathy — 1 report (8.33%)
10. Leukopenia — 1 report (8.33%)

Source database →

Frequently asked questions

Is Palbociclib 125mg approved in United States?

Palbociclib 125mg does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Palbociclib 125mg in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.